Date: 2016-12-30
Type of
information: Treatment of the first patient
phase: 1
Announcement: treatment of the first patient
Company: BeiGene (China)
Product: BGB-A317
Action
mechanism:
- monoclonal antibody//immune checkpoint inhibitor. BGB-A317 is an investigational humanized monoclonal antibody designed to bind to PD-1, a cell surface receptor that plays an important role in downregulating the immune system by preventing the activation of T-cells. BGB-A317 is being developed as a monotherapy and in combination with other therapies for the treatment of various cancers.
Disease: advanced solid tumors
Therapeutic
area: Cancer - Oncology
Country:
Trial
details:
Latest
news:
- • On December 30, 2016, BeiGene announced the dosing of the first patient in a Phase I clinical trial of BGB-A317, an anti-PD-1 monoclonal antibody, in mainland Chinese patients with advanced solid tumors. The Phase I open-label, multi-center study of BGB-A317 is designed to investigate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of BGB-A317 in Chinese patients with advanced solid tumors. Professor Yilong Wu from Guangdong General Hospital is the lead principal investigator of the study. The co-lead investigators are Professor Lin Shen and Professor Jun Guo, both of Beijing Cancer Hospital. Another phase I study of BGB-A317 is ongoing in Australia, New Zealand, the United States, and Taiwan.
Is
general: Yes
